Literature DB >> 11096336

Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients.

L Crevits1, J Versijpt, M Hanse, K De Ridder.   

Abstract

We wanted to compare clinical neurological and antisaccadic behavior before and after addition of a dopamine agonist to the usual antiparkinsonian drugs in advanced Parkinson's disease. Parkinson's patients in stage 3 and 4 of Hoehn and Yahr not yet taking a dopamine agonist were selected. In 20 patients, the treating neurologist decided to add pergolide. The dose of pergolide was adjusted by the treating neurologist according to clinical response. Antisaccades were studied by infrared oculography before and after addition of pergolide. Antisaccades are voluntary saccades in the opposite direction of an unanticipated visual target. The patients made more errors, i.e. they glanced to the target or they made no eye movement at all. In contradistinction to the global neurological improvement and the better motor scores, antisaccadic disturbances did not improve significantly with pergolide, except in younger patients. These findings suggest that antisaccadic alterations in patients with advanced Parkinson's disease could be multifaceted. Not only depletion of dopamine, but also non-dopaminergic dysfunctions could contribute. Cortical frontal lesions must also be taken into account. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11096336     DOI: 10.1159/000026694

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  9 in total

1.  Lisuride reduces involuntary periodic leg movements in spinocerebellar ataxia type 2 patients.

Authors:  Luis Velázquez-Pérez; Roberto Rodríguez-Labrada; Lázaro Álvarez-González; Raúl Aguilera-Rodríguez; Mario Álvarez Sánchez; Nalia Canales-Ochoa; Lourdes Galicia Polo; Reyes Haro-Valencia; Jacqueline Medrano-Montero; Yaimeé Vázquez-Mojena; Arnoy Peña-Acosta; Annelié Estupiñán-Rodríguez; Noemí Rodríguez Pupo
Journal:  Cerebellum       Date:  2012-12       Impact factor: 3.847

2.  Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's disease.

Authors:  Ashley J Hood; Silvia C Amador; Ashley E Cain; Kevin A Briand; Ali H Al-Refai; Mya C Schiess; Anne B Sereno
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

Review 3.  Cortical control of saccades in Parkinson disease and essential tremor.

Authors:  S Yerram; S Glazman; I Bodis-Wollner
Journal:  J Neural Transm (Vienna)       Date:  2012-08-28       Impact factor: 3.575

4.  Effect of subthalamic deep brain stimulation on turning kinematics and related saccadic eye movements in Parkinson disease.

Authors:  Corey A Lohnes; Gammon M Earhart
Journal:  Exp Neurol       Date:  2012-05-09       Impact factor: 5.330

Review 5.  Pharmacological treatment effects on eye movement control.

Authors:  James L Reilly; Rebekka Lencer; Jeffrey R Bishop; Sarah Keedy; John A Sweeney
Journal:  Brain Cogn       Date:  2008-12       Impact factor: 2.310

6.  Saccadic latency distributions in Parkinson's disease and the effects of L-dopa.

Authors:  A W Michell; Z Xu; D Fritz; S J G Lewis; T Foltynie; C H Williams-Gray; T W Robbins; R H S Carpenter; R A Barker
Journal:  Exp Brain Res       Date:  2006-03-17       Impact factor: 1.972

7.  Eye movement impairments in Parkinson's disease: possible role of extradopaminergic mechanisms.

Authors:  Elmar H Pinkhardt; Reinhart Jürgens; Dorothée Lulé; Johanna Heimrath; Albert C Ludolph; Wolfgang Becker; Jan Kassubek
Journal:  BMC Neurol       Date:  2012-02-29       Impact factor: 2.474

8.  A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease.

Authors:  Diliana Rebelo; Francisco Oliveira; Antero Abrunhosa; Cristina Januário; João Lemos; Miguel Castelo-Branco
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

Review 9.  Antisaccades in Parkinson's Disease: A Meta-Analysis.

Authors:  Josefine Waldthaler; Lena Stock; Justus Student; Johanna Sommerkorn; Stefan Dowiasch; Lars Timmermann
Journal:  Neuropsychol Rev       Date:  2021-03-19       Impact factor: 7.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.